Eli Lilly acquires LimmaTech: the advisors
Eli Lilly agreed to acquire LimmaTech Biologics — a Swiss clinical-stage biotech company developing vaccines for the prevention of life-threatening diseases — for up to USD 780 m in cash, inclusive of an upfront payment and additional potential payments based upon the achievement of certain clinical and regulatory milestones.
In connection with the deal, Homburger advised Eli Lilly, while Vischer represented LimmaTech Biologics.
The Homburger team
The Homburger team advising Eli Lilly includes Anna Peter (pictured), Bianca Nedwed, Daniel Kuhn, Jana Waldvogel and Ivo Graf (all corporate/M&A), Joel Fink (IP / IT), Jeremy Reichlin and Giulia Menegon (both employment and executive compensation) as well as Stefan Oesterhelt and Juliette Buob (both tax).
The Vischer team
The Vischer team working on the mattter includes partner Matthias Staehelin, managing associate Pauline Pfirter, managing associate Luzius Zumstein, associate Natacha Tang and junior associate Oliver Fischer (all corporate/M&A). The lineup further comprehends partner Marc Prinz (employment) as well as partner Nadia Tarolli and managing associate Michelle Bruni (both tax).
